You are here: Industry Insights > Market News > Glenmark receives ANDA approval for Ranolazine Extended-Release Tablets

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

Glenmark receives ANDA approval for Ranolazine Extended-Release Tablets

biospectrumasiaJuly 09, 2019

Tag: Glenmark , ANDA , Ranolazine Extended-Release Tablets

Favorites

Glenmark Pharmaceuticals Inc. has been granted final approval by the United States Food & Drug Administration for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg, a generic version of Ranexa® Extended-Release Tablets, 500 mg and 1,000 mg, of Gilead Sciences, Inc.

According to IQVIATM sales data for the 12 month period ending May 2019, the Ranexa® Extended-Release Tablets, 500 mg and 1,000 mg market2 achieved annual sales of approximately $929.0 million.

Glenmark’s current portfolio consists of 158 products authorized for distribution in the U.S. marketplace and 57 ANDA’s pending approval with the USFDA.

Previous:AG Mednet, Median Technologies to conduct clinical programs in China

Next:Daewoong Pharmaceutical introduced the excellence of NABOTA® (Prabotulinumtoxin A)

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Glenmark receives ANDA approval for Ranolazine Extended-Release Tablets | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Ashwagandha extract WITHANIA SOMNIFERA extract Ashwaganda

Hydroxypropyl Betadex oral grade USP Standard

high standard and high quality Human Prothrombin Complex by Hualan biological

GMP Standard Factory Supply Amygdalin 98%

Ergot secale cornutum ErgotErgota spurred rye extract ergosterol ergosterin Ergosterol Standard Hydr

High-standard and high quality Influenza Vaccine (Split virion), inactivated

pharmaceutical Oxytocin Acetate(GMP standard product) Peptide

LGJ-12S Multi Manifold Standard Type Experimental Freeze Dryer

International standard Group ACYW135 Meningococcal Polysaccharide Vaccine with lower adverse effect

LGJ-18 Multi Manifold Standard Type Experimental Freeze Dryer

Glenmark receives ANDA approval for Ranolazine Extended-Release Tablets

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>